Author:
Takeuchi Makoto,Yamauchi Takahiro,Yoshida Isao,Soda Ryo,Ueda Takanori,Takahashi Kiyoshi
Publisher
Springer Science and Business Media LLC
Reference9 articles.
1. Seyffart G. Drugs in renal failure: dosing guidelines for frequently used drugs in end-stage renal disease and dialysis patients.Blood Purif. 1985;3:140–168.
2. Shimada N, Ueda T, Yokoshita T, Oh-ishi J, Oh-oka T. A sensitive and specific radioimmunoassay for 1-beta-D-arabinofuranosyl cytosine.Cancer Lett. 1984;24:173–178.
3. Smith GA, Damon LE, Rugo HS, Ries CA, Linker CA. High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency.J Clin Oncol. 1997;15:833–839.
4. Damon LE, Plunkett W, Linker CA. Plasma and cerebrospinal fluid pharmacyokinetics of 1-beta-D-arabinofuranosylcytosine and 1-beta-D-arabinofuranosyluracil following the repeated intravenous administration of highand intermediate-dose 1-beta-D-arabinofuranosylcytosine.Cancer Res. 1991;51:4141–4145.
5. Poschl JM, Klaus G, Querfeld U, Ludwig R, Mehls O. Chemotherapy with cytosine arabinoside in a child with Burkitt’s lymphoma on maintenance hemodialysis and hemofiltration.Ann Uematol 1993;67:37–39.
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献